Display options
Cite
Hamajima K, Hamamura K, Chen A, et al. Suppression of osteoclastogenesis via α2-adrenergic receptors. Biomed Rep. 2018;8(5):407-416doi: 10.3892/br.2018.1075.
Hamajima, K., Hamamura, K., Chen, A., Yokota, H., Mori, H., Yo, S., Kondo, H., Tanaka, K., Ishizuka, K., Kodama, D., Hirai, T., Miyazawa, K., Goto, S., & Togari, A. (2018). Suppression of osteoclastogenesis via α2-adrenergic receptors. Biomedical reports, 8(5), 407-416. https://doi.org/10.3892/br.2018.1075
Hamajima, Kosuke, et al. "Suppression of osteoclastogenesis via α2-adrenergic receptors." Biomedical reports vol. 8,5 (2018): 407-416. doi: https://doi.org/10.3892/br.2018.1075
Hamajima K, Hamamura K, Chen A, Yokota H, Mori H, Yo S, Kondo H, Tanaka K, Ishizuka K, Kodama D, Hirai T, Miyazawa K, Goto S, Togari A. Suppression of osteoclastogenesis via α2-adrenergic receptors. Biomed Rep. 2018 May;8(5):407-416. doi: 10.3892/br.2018.1075. Epub 2018 Mar 09. PMID: 29725523; PMCID: PMC5920467.
Copy Download .nbib Format: NLM
Share it on

Biomed Rep. 2018 May;8(5):407-416. doi: 10.3892/br.2018.1075. Epub 2018 Mar 09.

Suppression of osteoclastogenesis via α2-adrenergic receptors.

Biomedical reports

Kosuke Hamajima, Kazunori Hamamura, Andy Chen, Hiroki Yokota, Hironori Mori, Shoyoku Yo, Hisataka Kondo, Kenjiro Tanaka, Kyoko Ishizuka, Daisuke Kodama, Takao Hirai, Ken Miyazawa, Shigemi Goto, Akifumi Togari

Affiliations

  1. Department of Pharmacology, School of Dentistry, Aichi-Gakuin University, Nagoya, Aichi 464-8650, Japan.
  2. Department of Orthodontics, School of Dentistry, Aichi-Gakuin University, Nagoya, Aichi 464-8650, Japan.
  3. Department of Biomedical Engineering, Indiana University - Purdue University Indianapolis, Indianapolis, IN 46202, USA.
  4. Laboratory of Neuropharmacology, School of Pharmacy, Aichi-Gakuin University, Nagoya, Aichi 464-8650, Japan.
  5. Laboratory of Medical Resources, School of Pharmacy, Aichi-Gakuin University, Nagoya, Aichi 464-8650, Japan.

PMID: 29725523 PMCID: PMC5920467 DOI: 10.3892/br.2018.1075

Abstract

The sympathetic nervous system is known to regulate osteoclast development. However, the involvement of α2-adrenergic receptors (α2-ARs) in osteoclastogenesis is not well understood. In the present study, their potential role in osteoclastogenesis was investigated. Guanabenz, clonidine and xylazine were used as agonists of α2-ARs, while yohimbine and idazoxan were employed as antagonists. Using RAW264.7 pre-osteoclast and primary bone marrow cells, the mRNA expression of the osteoclast-related genes nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), tartrate-resistant acid phosphatase (TRAP) and cathepsin K was evaluated following induction with receptor activator of nuclear factor κB ligand (RANKL). TRAP staining was also conducted to assess effects on osteoclastogenesis in mouse bone marrow cells

Keywords: agonist; antagonist; osteoclast; osteoclastogenesis; α2-adrenergic receptors

References

  1. Nature. 1999 Nov 11;402(6758):181-4 - PubMed
  2. J Exp Med. 2011 Apr 11;208(4):841-51 - PubMed
  3. Methods. 2001 Dec;25(4):402-8 - PubMed
  4. Sci Rep. 2017 May 16;7(1):1944 - PubMed
  5. Brain Res. 2000 Feb 21;856(1-2):245-9 - PubMed
  6. Trends Pharmacol Sci. 2002 Feb;23(2):89-95 - PubMed
  7. Arch Biochem Biophys. 2009 Feb;482(1-2):96-103 - PubMed
  8. Mol Pharmacol. 2003 Dec;64(6):1271-6 - PubMed
  9. Br J Pharmacol. 2016 Mar;173(6):1058-69 - PubMed
  10. Arch Oral Biol. 2007 Aug;52(8):778-85 - PubMed
  11. J Pharmacol Exp Ther. 2009 Oct;331(1):35-44 - PubMed
  12. J Biol Chem. 2013 Oct 25;288(43):31370-85 - PubMed
  13. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9950-5 - PubMed
  14. FASEB J. 2014 Nov;28(11):4901-13 - PubMed
  15. J Bone Miner Metab. 2013 Nov;31(6):618-28 - PubMed
  16. Calcif Tissue Int. 2014 Jan;94(1):140-51 - PubMed
  17. Matrix Biol. 2014 Sep;38:22-35 - PubMed
  18. Br J Pharmacol. 2013 Nov;170(6):1167-76 - PubMed
  19. Eur J Pharmacol. 2011 Mar 1;654(1):1-9 - PubMed
  20. J Bone Miner Res. 2011 Mar;26(3):591-603 - PubMed
  21. Cell Metab. 2006 Nov;4(5):341-8 - PubMed
  22. Nature. 1998 Dec 3;396(6710):474-7 - PubMed
  23. Pflugers Arch. 2017 Jun;469(5-6):725-737 - PubMed
  24. Med Res Rev. 2005 Jul;25(4):398-426 - PubMed
  25. Cell Signal. 2015 Feb;27(2):353-62 - PubMed
  26. Osteoporos Int. 2016 Mar;27(3):1063-1071 - PubMed
  27. Biochim Biophys Acta. 2003 May 12;1640(2-3):137-42 - PubMed
  28. Br J Pharmacol. 2013 Mar;168(5):1230-9 - PubMed
  29. Biochem Pharmacol. 2001 Mar 1;61(5):579-86 - PubMed
  30. Cell Signal. 2014 Nov;26(11):2358-69 - PubMed
  31. Microsc Res Tech. 2002 Jul 15;58(2):77-84 - PubMed
  32. Expert Opin Ther Targets. 2005 Oct;9(5):931-40 - PubMed
  33. Am J Physiol Endocrinol Metab. 2013 Mar 1;304(5):E507-15 - PubMed
  34. J Orthop Res. 2011 May;29(5):740-5 - PubMed
  35. Mol Pharmacol. 2001 Mar;59(3):532-42 - PubMed
  36. Science. 1996 Aug 9;273(5276):801-3 - PubMed
  37. Basic Clin Pharmacol Toxicol. 2011 Jun;108(6):365-70 - PubMed
  38. Biochem Pharmacol. 2007 Apr 15;73(8):1076-83 - PubMed

Publication Types